MARKET DEFINITION

The term "antiretroviral therapy" (ART) refers to HIV treatment. A daily HIV treatment regimen, or a mix of HIV medications, is taken as part of ART. ART is advised for all HIV-positive individuals. A person's viral load must be decreased to an undetectable level as the primary objective of HIV treatment. Next-generation HIV therapies include integrase inhibitors, NRTIs, and combination medication, among other drug classes. These drugs have a longer duration of action, which eliminates the need for daily injections or pills. Other next generation HIV therapies under development are anti-HIV antibody infusions, 6-month ART implants, and monthly injections of continuously released ART among others.

MARKET DYNAMICS

The global market for HIV drugs has grown quickly as major participants in the biotechnology and pharmaceutical industries have boosted their adoption of cutting-edge medication combinations. Innovation and the introduction of new technology promote improvements in biological processes. The demand has been fueled by government efforts to increase public awareness. Another factor boosting market expansion is the rise of HIV/AIDS cases. A sizable patient base's demand for novel, long-acting medications with lower consumption frequencies has been driving the industry. However, a lack of access to regular treatment, especially in underdeveloped countries can hamper market growth. Favorable governmental policies toward curbing infection rates are expected to offer lucrative opportunities for growth to the key players.

REPORT SCOPE

The report titled “Global Next Generation HIV Therapies Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Next Generation HIV Therapies market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global next generation HIV therapies market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global next generation HIV therapies Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Next Generation HIV Therapies Market is segmented based on drug class, distribution channel, and region. Based on drug class, the market has been segmented into integrase inhibitors, non- nucleoside reverse transcriptase inhibitors (NRTIs), combination HIV medicines, and others, whereas based on distribution channel, the market comprises hospital pharmacies, retail pharmacies, online pharmacies, and others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the next generation HIV therapies market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Next Generation HIV Therapies market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Next Generation HIV Therapies market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the next generation HIV therapies industry in the past three years.

Key players in the Global Next Generation HIV Therapies Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• ViiV Healthcare
• GlaxoSmithKline plc
• Gilead Sciences, Inc.
• Merck Sharp & Dohme Corp.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• AbbVie Inc.
• Genentech, Inc.
• Mylan N.V.

COVID-19 IMPACT ANALYSIS ON GLOBAL NEXT GENERATION HIV THERAPIES MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global next generation HIV therapies market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the next generation HIV therapies market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

• The report offers comprehensive data on the next generation HIV therapies market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity

Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective

Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Drug Class Trends
3.2.2. Distribution Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Next Generation HIV Therapies Market
3.6. COVID-19 Impact Assessment in Next Generation HIV Therapies Market
3.6.1. Impact Assessment on Global Next Generation HIV Therapies Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4. Global Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
4.1. Global Next Generation HIV Therapies Market Share, By Drug Class, 2017 - 2028 (USD Million)
4.1.1. Integrase Inhibitors
4.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
4.1.3. Combination HIV Medicines
4.1.4. Others

Chapter 5. Global Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
5.1. Global Next Generation HIV Therapies Market Share, By Distribution Channel, 2017 - 2028 (USD Million)
5.1.1. Hospital Pharmacies
5.1.2. Retail Pharmacies
5.1.3. Online Pharmacies
5.1.4. Others

Chapter 6. Global Next Generation HIV Therapies Market Overview, By Geography, 2017 - 2028 (USD Million)
6.1. Global Next Generation HIV Therapies Market Share, By Geography, 2017 - 2028 (USD Million)
6.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)
6.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 7. North America Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
7.1. North America Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
7.1.1. Market size and projections, 2017 - 2028 (USD Million)
7.1.2. North America Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
7.1.3. North America Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
7.2. North America Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
7.2.1. U.S. Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
7.2.1.1. U.S. Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
7.2.1.2. U.S. Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
7.2.2. Canada Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
7.2.2.1. Canada Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
7.2.2.2. Canada Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
7.2.3. Mexico Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
7.2.3.1. Mexico Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
7.2.3.2. Mexico Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 8. Europe Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. Europe Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market size and projections, 2017 - 2028 (USD Million)
8.1.2. Europe Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.1.3. Europe Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2. Europe Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. Germany Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. Germany Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.1.2. Germany Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.2. France Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. France Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.2.2. France Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.3. UK Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. UK Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.3.2. UK Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.4. Italy Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.4.1. Italy Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.4.2. Italy Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.5. Spain Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.5.1. Spain Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.5.2. Spain Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.6. NORDIC Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.6.1. NORDIC Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.6.2. NORDIC Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.7. Russia and CIS Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.7.1. Russia and CIS Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.7.2. Russia and CIS Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.8. Rest of Europe Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
8.2.8.1. Rest of Europe Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.8.2. Rest of Europe Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 9. Asia Pacific Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Asia Pacific Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market size and projections, 2017 - 2028 (USD Million)
9.1.2. Asia Pacific Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.1.3. Asia Pacific Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2. Asia Pacific Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. India Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. India Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.1.2. India Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.2. China Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. China Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.2.2. China Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.3. Japan Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Japan Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.3.2. Japan Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.4. ASEAN Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. ASEAN Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.4.2. ASEAN Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.5. South Korea Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. South Korea Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.5.2. South Korea Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.6. Australia Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. Australia Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.6.2. Australia Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.7. Rest of Asia Pacific Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Rest of Asia Pacific Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.7.2. Rest of Asia Pacific Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 10. South America Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. South America Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market size and projections, 2017 - 2028 (USD Million)
10.1.2. South America Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.1.3. South America Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2. South America Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Brazil Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Brazil Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.1.2. Brazil Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.2. Argentina Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Argentina Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.2.2. Argentina Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.3. Rest of South America Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Rest of South America Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.3.2. Rest of South America Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 11. Middle East & Africa Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Middle East & Africa Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market size and projections, 2017 - 2028 (USD Million)
11.1.2. Middle East & Africa Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.1.3. Middle East & Africa Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2. Middle East & Africa Next Generation HIV Therapies Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. GCC Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. GCC Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.1.2. GCC Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.2. South Africa Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. South Africa Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.2.2. South Africa Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.3. Rest of Middle East & Africa Next Generation HIV Therapies Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of Middle East & Africa Next Generation HIV Therapies Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.3.2. Rest of Middle East & Africa Next Generation HIV Therapies Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 12. Competitive Landscape
12.1. Competitive Environment, 2021
12.2. Strategic Framework
12.2.1. Partnership/Collaborations/Agreement
12.2.2. Expansion
12.2.3. Mergers & Acquisitions
12.2.4. New Product Development

Chapter 13. Key Vendor Analysis
13.1. ViiV Healthcare
13.1.1. Business Overview
13.1.2. Product Benchmarking
13.1.3. Financial Data
13.1.4. Strategic Overview
13.1.5. Key Developments
13.1.6. SWOT Analysis
13.2. GlaxoSmithKline plc
13.2.1. Business Overview
13.2.2. Product Benchmarking
13.2.3. Financial Data
13.2.4. Strategic Overview
13.2.5. Key Developments
13.2.6. SWOT Analysis
13.3. Giled Sciences, Inc.
13.3.1. Business Overview
13.3.2. Product Benchmarking
13.3.3. Financial Data
13.3.4. Strategic Overview
13.3.5. Key Developments
13.3.6. SWOT Analysis
13.4. Merck Sharp & Dohme Corp.
13.4.1. Business Overview
13.4.2. Product Benchmarking
13.4.3. Financial Data
13.4.4. Strategic Overview
13.4.5. Key Developments
13.4.6. SWOT Analysis
13.5. Bristol-Myers Squibb Company
13.5.1. Business Overview
13.5.2. Product Benchmarking
13.5.3. Financial Data
13.5.4. Strategic Overview
13.5.5. Key Developments
13.5.6. SWOT Analysis
13.6. Janssen Pharmaceuticals, Inc.
13.6.1. Business Overview
13.6.2. Product Benchmarking
13.6.3. Financial Data
13.6.4. Strategic Overview
13.6.5. Key Developments
13.6.6. SWOT Analysis
13.7. Boehringer Ingelheim International GmbH
13.7.1. Business Overview
13.7.2. Product Benchmarking
13.7.3. Financial Data
13.7.4. Strategic Overview
13.7.5. Key Developments
13.7.6. SWOT Analysis
13.8. AbbVie Inc.
13.8.1. Business Overview
13.8.2. Product Benchmarking
13.8.3. Financial Data
13.8.4. Strategic Overview
13.8.5. Key Developments
13.8.6. SWOT Analysis
13.9. Genetech, Inc.
13.9.1. Business Overview
13.9.2. Product Benchmarking
13.9.3. Financial Data
13.9.4. Strategic Overview
13.9.5. Key Developments
13.9.6. SWOT Analysis
13.10. Mylan N.V.
13.10.1. Business Overview
13.10.2. Product Benchmarking
13.10.3. Financial Data
13.10.4. Strategic Overview
13.10.5. Key Developments
13.10.6. SWOT Analysis

Chapter 14. Future Outlook of the Market
Disclaimer